U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H30N2O4
Molecular Weight 494.5809
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ASP-7991

SMILES

C[C@@H](NC[C@H]1CN(C[C@@H]1C2=CC=CC=C2)C(=O)OC3=CC=C(C=C3)C(O)=O)C4=C5C=CC=CC5=CC=C4

InChI

InChIKey=BJFBVTUZMDZDML-ZCAZLTSLSA-N
InChI=1S/C31H30N2O4/c1-21(27-13-7-11-22-10-5-6-12-28(22)27)32-18-25-19-33(20-29(25)23-8-3-2-4-9-23)31(36)37-26-16-14-24(15-17-26)30(34)35/h2-17,21,25,29,32H,18-20H2,1H3,(H,34,35)/t21-,25+,29-/m1/s1

HIDE SMILES / InChI

Molecular Formula C31H30N2O4
Molecular Weight 494.5809
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Wed Apr 02 21:24:09 GMT 2025
Edited
by admin
on Wed Apr 02 21:24:09 GMT 2025
Record UNII
S5D6NEU9CW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ASP7991
Preferred Name English
ASP-7991
Common Name English
4-Carboxyphenyl (3S,4S)-3-[[[(1R)-1-(1-naphthalenyl)ethyl]amino]methyl]-4-phenyl-1-pyrrolidinecarboxylate
Systematic Name English
1-Pyrrolidinecarboxylic acid, 3-[[[(1R)-1-(1-naphthalenyl)ethyl]amino]methyl]-4-phenyl-, 4-carboxyphenyl ester, (3S,4S)-
Systematic Name English
Code System Code Type Description
FDA UNII
S5D6NEU9CW
Created by admin on Wed Apr 02 21:24:09 GMT 2025 , Edited by admin on Wed Apr 02 21:24:09 GMT 2025
PRIMARY
PUBCHEM
15605151
Created by admin on Wed Apr 02 21:24:09 GMT 2025 , Edited by admin on Wed Apr 02 21:24:09 GMT 2025
PRIMARY
CAS
915387-82-5
Created by admin on Wed Apr 02 21:24:09 GMT 2025 , Edited by admin on Wed Apr 02 21:24:09 GMT 2025
PRIMARY
Related Record Type Details
METABOLITE INACTIVE -> PARENT
MAJOR
PARENT -> METABOLITE INACTIVE
METABOLITE INACTIVE -> PARENT
MAJOR
Related Record Type Details
ACTIVE MOIETY
Suppresses parathyroid hormone (PTH) secretion in the treatment of secondary hyperparathyroidism.